Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...
BiLSTM, an ICD-11 automatic coding model using MC-BERT and label attention. Experiments on clinical records show 83.86% ...
An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial ...
The state Plant Board on Wednesday deferred a decision on a proposal to establish a new classification for pesticides ...
Dr. Daniel Jernigan, former director of the CDC’s National Center for Emerging and Zoonotic Infectious Diseases, calls the ...
FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability ...
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product ...
A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...
The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...
New options for testing and treating some of the most common sexually transmitted diseases are becoming available.
32 Biosciences revealed its plan to launch a $40 million Series A at this year’s J.P Morgan Healthcare conference, to advance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback